Kistler-Tiffany Companies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kistler-Tiffany Companies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$55.5K	Hold	640	–	–	0.01%	479
2023 Q1	$62.2K	Hold	640	–	–	0.01%	415
2022 Q4	$66.2K	Sell	640 -740	-54%	-$69.5K	0.01%	393
2022 Q3	$117K	Hold	1,380	–	–	0.03%	260
2022 Q2	$114K	Buy	1,380 +65	+5%	+$5.17K	0.02%	270
2022 Q1	$101K	Buy	1,315 +20	+2%	+$1.67K	0.02%	299
2021 Q4	$114K	Buy	1,295 +30	+2%	+$2.48K	0.02%	263
2021 Q3	$98K	Buy	1,265 +185	+17%	+$14.6K	0.02%	278
2021 Q2	$90K	Buy	1,080 +142	+15%	+$11.3K	0.02%	289
2021 Q1	$71K	Buy	938 +130	+16%	+$10.6K	0.02%	287
2020 Q4	$71K	Sell	808 -320	-28%	-$25.4K	0.02%	262
2020 Q3	$86K	Sell	1,128 -510	-31%	-$51.6K	0.03%	228
2020 Q2	$202K	Sell	1,638 -882	-35%	-$87.7K	0.07%	137
2020 Q1	$213K	Hold	2,520	–	–	0.08%	135
2019 Q4	$213K	Hold	2,520	–	–	0.07%	138
2019 Q3	$170K	Buy	2,520 +540	+27%	+$41.6K	0.06%	146
2019 Q2	$170K	Buy	1,980 +1,708	+628%	+$146K	0.06%	142
2019 Q1	$24K	Buy	+272	New	+$25.2K	0.01%	325

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Kistler-Tiffany Companies's BMRN Position: Q2 2023 in Review

Kistler-Tiffany Companies held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2023 at 640 shares worth $55.5K. The position accounts for 0.01% of the portfolio, ranked #479.

Kistler-Tiffany Companies first reported a position in BMRN in Q1 2019 and has held it in 18 quarters since. The position peaked at $213K in Q1 2020. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Kistler-Tiffany Companies held 640 shares of BioMarin Pharmaceuticals worth $55.5K as of Q2 2023.
Kistler-Tiffany Companies left its BioMarin Pharmaceuticals share count unchanged in Q2 2023.
BioMarin Pharmaceuticals made up 0.01% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #479 holding.
Kistler-Tiffany Companies first reported a position in BioMarin Pharmaceuticals in Q1 2019 and has held it in 18 quarters since.
Kistler-Tiffany Companies's BioMarin Pharmaceuticals position peaked at $213K in Q1 2020.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.